Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Phizackerley

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Drug and Therapeutics Bulletin|February 1, 2020
Registering our interestDavid Phizackerley
BMJ (Clinical Research Ed.)|June 7, 2022
Three more points about Paxlovid for covid-19David Phizackerley
Drug and Therapeutics Bulletin|February 12, 2024
Protecting consumers: a rich legacyDavid Phizackerley
Drug and Therapeutics Bulletin|March 3, 2025
Paying the priceDavid Phizackerley
Drug and Therapeutics Bulletin|May 2, 2020
Deprescribing in the time of covid-19David Phizackerley
Drug and Therapeutics Bulletin|September 27, 2018
AF screening: who is calling the tune?David Phizackerley
Drug and Therapeutics Bulletin|April 20, 2021
Time for transparencyDavid Phizackerley
Drug and Therapeutics Bulletin|April 10, 2025
Polypill primary prevention: panacea or problematic polypharmacy?David Phizackerley
Drug and Therapeutics Bulletin|May 31, 2019
If the drugs don't workDavid Phizackerley
BMJ (Clinical Research Ed.)|January 15, 2024
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5David Phizackerley
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Drug and Therapeutics Bulletin|February 1, 2020
Registering our interestDavid Phizackerley
BMJ (Clinical Research Ed.)|June 7, 2022
Three more points about Paxlovid for covid-19David Phizackerley
Drug and Therapeutics Bulletin|February 12, 2024
Protecting consumers: a rich legacyDavid Phizackerley
Drug and Therapeutics Bulletin|March 3, 2025
Paying the priceDavid Phizackerley
Drug and Therapeutics Bulletin|May 2, 2020
Deprescribing in the time of covid-19David Phizackerley
Drug and Therapeutics Bulletin|September 27, 2018
AF screening: who is calling the tune?David Phizackerley
Drug and Therapeutics Bulletin|April 20, 2021
Time for transparencyDavid Phizackerley
Drug and Therapeutics Bulletin|April 10, 2025
Polypill primary prevention: panacea or problematic polypharmacy?David Phizackerley
Drug and Therapeutics Bulletin|May 31, 2019
If the drugs don't workDavid Phizackerley
BMJ (Clinical Research Ed.)|January 15, 2024
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5David Phizackerley
Pageof 4